Luminor0.025%

Luminor is a selective alpha-2 adrenergic agonist used in two distinct formulations for different, FDA-approved indications:

Established/FDA-approved uses

• Ophthalmic solution (0.15%/0.2%): Lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
• Topical gel (0.33%): Treatment of persistent (non-transient) facial erythema associated with rosacea in adults.

Adjunct use

Luminor ophthalmic solution is commonly used as an adjunct to other IOP-lowering agents (e.g. beta-blockers, prostaglandin analogues) when a single agent does not achieve adequate pressure control, and is available in fixed-dose combination products with timolol or brimonidine/brinzolamide for this purpose.

Off-label use

Luminor ophthalmic solution is sometimes used off-label short-term to reduce conjunctival hyperemia (redness) prior to certain ophthalmic procedures, but this is not an FDA-labeled indication.

Luminor is a highly selective alpha-2 adrenergic receptor agonist. In ophthalmic use it reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. In dermatologic use, its alpha-2 agonist activity produces direct vasoconstriction of dilated facial blood vessels, temporarily reducing the visible redness (erythema) associated with rosacea.

Luminor is not a cure for glaucoma or rosacea; it manages the underlying pressure or visible redness and requires continued, regular use as directed by a physician.

Brimonidine Tartrate is a relatively selective alpha-2 adrenoceptor agonist with minimal effect on cardiovascular and pulmonary parameters at recommended doses.

Ophthalmic mechanism

Stimulation of alpha-2 receptors in the ciliary body reduces aqueous humor formation, and stimulation of receptors involved in uveoscleral drainage increases outflow, both lowering intraocular pressure. Onset of IOP reduction occurs within about 1 hour, with peak effect at 2 hours.

Dermatologic mechanism

Topical alpha-2 agonism on dermal vascular smooth muscle produces direct vasoconstriction of dilated cutaneous vessels, reducing visible erythema; effect typically begins within 30 minutes and lasts up to 12 hours.

Ophthalmic solution is instilled directly into the conjunctival sac of the affected eye(s); if using other ophthalmic products, space administration at least 5-10 minutes apart. Topical gel is applied thinly and evenly to clean, dry facial skin once daily; do not apply to broken or irritated skin, and avoid contact with eyes and mucous membranes.

Luminor has the following well-established, clinically significant interactions:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use is contraindicated; MAOIs may interfere with the metabolism of Luminor and increase systemic adrenergic effects.
• CNS depressants (alcohol, barbiturates, opioids, sedatives, anesthetics): May cause additive sedation and CNS depression with Luminor.
• Antihypertensive agents and cardiac glycosides: Luminor may have an additive or potentiating effect on blood pressure lowering and heart rate reduction.
• Tricyclic antidepressants: May blunt the systemic hypotensive effect of alpha-2 agonists like Luminor and theoretically affect its ocular pressure-lowering response; use with caution.

Ophthalmic solution

Common: ocular hyperemia (redness), burning or stinging on instillation, blurred vision, foreign body sensation, itching, dry mouth, headache, drowsiness, and allergic conjunctivitis. Less common: eye allergy, eyelid swelling, and (rarely) systemic effects such as fatigue or dizziness.

Topical gel

Common: erythema, flushing, skin irritation, burning or stinging sensation, contact dermatitis, and pruritus at the application site.

Most reactions to Luminor are mild to moderate and localized; patients should report severe or persistent reactions to their physician.

Luminor has not been adequately studied in pregnant women. Animal reproduction studies have not shown clear evidence of fetal harm, but human data are limited. Luminor should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

It is not known whether Luminor is excreted in human breast milk. Because many drugs are excreted in breast milk and systemic absorption can occur (particularly with ophthalmic use in infants), caution is advised and a physician should be consulted before using Luminor while breastfeeding.

Luminor should be used with caution in patients with:

• Severe or unstable cardiovascular disease.
• Depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
• Renal or hepatic impairment (limited data on systemic accumulation).

Luminor ophthalmic solution may cause drowsiness or blurred vision; patients should use caution when driving or operating machinery. Contact lenses should be removed before instillation and may be reinserted 15 minutes later. Keep the container tightly closed and avoid contaminating the tip. For the topical gel, avoid application to broken, irritated, or eczematous skin, and avoid contact with eyes and mucous membranes. Rebound erythema may occasionally occur after discontinuing the gel. See Contraindications for absolute restrictions and Use in Special Populations for pediatric risk.

Store at room temperature (below 30°C), away from light and moisture. Keep the bottle/tube tightly closed and out of reach of children.

Pediatric use

Luminor is contraindicated in children under 2 years of age due to risk of serious CNS depression. In children aged 2 years and older, safety and efficacy have been evaluated for ophthalmic use, but caution is advised due to lower body weight increasing systemic exposure risk; the topical gel's safety and efficacy in children under 18 years have not been established.

Elderly

No specific dose adjustment is required for Luminor in elderly patients, though age-related cardiovascular changes warrant routine clinical monitoring.

Renal/hepatic impairment

Limited data are available; use Luminor with caution and monitor patients with significant renal or hepatic impairment.

Alpha-2 adrenergic agonist

Category B